The identification of the genomic sequence of the breakpoint flanking regions of the ETV6‐RUNX1 translocation should be the best strategy to monitor minimal residual disease (MRD) in patients with ETV6‐RUNX1‐positive ALL. Here, RUNX1 is linked to acute lymphoblastic leukemia.